Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Making HSCs in vitro: don't forget the hemogenic endothelium.

Blaser BW, Zon LI.

Blood. 2018 Aug 8. pii: blood-2018-04-784140. doi: 10.1182/blood-2018-04-784140. [Epub ahead of print]

PMID:
30089629
2.

CXCR1 remodels the vascular niche to promote hematopoietic stem and progenitor cell engraftment.

Blaser BW, Moore JL, Hagedorn EJ, Li B, Riquelme R, Lichtig A, Yang S, Zhou Y, Tamplin OJ, Binder V, Zon LI.

J Exp Med. 2017 Apr 3;214(4):1011-1027. doi: 10.1084/jem.20161616. Epub 2017 Mar 28.

3.

Generation of Parabiotic Zebrafish Embryos by Surgical Fusion of Developing Blastulae.

Hagedorn EJ, Cillis JL, Curley CR, Patch TC, Li B, Blaser BW, Riquelme R, Zon LI, Shah DI.

J Vis Exp. 2016 Jun 11;(112). doi: 10.3791/54168.

4.

Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation.

Blaser BW, Kim HT, Alyea EP 3rd, Ho VT, Cutler C, Armand P, Koreth J, Antin JH, Plutzky J, Soiffer RJ.

Biol Blood Marrow Transplant. 2012 Apr;18(4):575-83. doi: 10.1016/j.bbmt.2011.08.003. Epub 2011 Aug 11.

5.

In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis.

Guimond M, Freud AG, Mao HC, Yu J, Blaser BW, Leong JW, Vandeusen JB, Dorrance A, Zhang J, Mackall CL, Caligiuri MA.

J Immunol. 2010 Mar 15;184(6):2769-75. doi: 10.4049/jimmunol.0900685. Epub 2010 Feb 8.

6.

A novel mouse model for the aggressive variant of NK cell and T cell large granular lymphocyte leukemia.

Yokohama A, Mishra A, Mitsui T, Becknell B, Johns J, Curphey D, Blaser BW, Vandeusen JB, Mao H, Yu J, Caligiuri MA.

Leuk Res. 2010 Feb;34(2):203-9. doi: 10.1016/j.leukres.2009.06.031. Epub 2009 Aug 5.

7.

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.

Romagné F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM Jr, Blaser BW, Della Chiesa M, Moretta A, Vivier E, Caligiuri MA, Velardi A, Wagtmann N.

Blood. 2009 Sep 24;114(13):2667-77. doi: 10.1182/blood-2009-02-206532. Epub 2009 Jun 24.

8.

The PP2A inhibitor SET regulates natural killer cell IFN-gamma production.

Trotta R, Ciarlariello D, Dal Col J, Allard J 2nd, Neviani P, Santhanam R, Mao H, Becknell B, Yu J, Ferketich AK, Thomas B, Modi A, Blaser BW, Perrotti D, Caligiuri MA.

J Exp Med. 2007 Oct 1;204(10):2397-405. Epub 2007 Sep 17.

9.

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D.

J Clin Invest. 2007 Sep;117(9):2408-21.

10.

Induction of folate receptor type beta in a bone marrow engraftment model of acute myelogenous leukemia.

Blaser BW, Gonit M, Qi H, Shatnawi A, Guimond M, Lee RJ, Ratnam M.

Leukemia. 2007 Oct;21(10):2233-5. Epub 2007 Jun 7. No abstract available.

PMID:
17554378
11.

Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.

Wang L, Wang J, Blaser BW, Duchemin AM, Kusewitt DF, Liu T, Caligiuri MA, Briesewitz R.

Blood. 2007 Sep 15;110(6):2075-83. Epub 2007 May 30.

12.

Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cells.

Becknell B, Hughes TL, Freud AG, Blaser BW, Yu J, Trotta R, Mao HC, Caligiuri de Jesús ML, Alghothani M, Benson DM Jr, Lehman A, Jarjoura D, Perrotti D, Bates MD, Caligiuri MA.

Blood. 2007 Mar 15;109(6):2481-7. Epub 2006 Nov 16.

13.

Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity.

Blaser BW, Schwind NR, Karol S, Chang D, Shin S, Roychowdhury S, Becknell B, Ferketich AK, Kusewitt DF, Blazar BR, Caligiuri MA.

Blood. 2006 Oct 1;108(7):2463-9. Epub 2006 Jun 6.

14.

Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35.

Pichiorri F, Trapasso F, Palumbo T, Aqeilan RI, Drusco A, Blaser BW, Iliopoulos D, Caligiuri MA, Huebner K, Croce CM.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3494-501. Erratum in: Clin Cancer Res. 2016 Dec 15;22(24):6304.

15.

Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells.

Yu J, Wei M, Becknell B, Trotta R, Liu S, Boyd Z, Jaung MS, Blaser BW, Sun J, Benson DM Jr, Mao H, Yokohama A, Bhatt D, Shen L, Davuluri R, Weinstein M, Marcucci G, Caligiuri MA.

Immunity. 2006 May;24(5):575-90.

16.

Tumor growth impedes natural-killer-cell maturation in the bone marrow.

Richards JO, Chang X, Blaser BW, Caligiuri MA, Zheng P, Liu Y.

Blood. 2006 Jul 1;108(1):246-52. Epub 2006 Mar 23.

17.

Autologous immune strategies to reduce the risk of leukemic relapse: consideration for IL-15.

Blaser BW, Caligiuri MA.

Best Pract Res Clin Haematol. 2006;19(2):281-92. Review.

PMID:
16516125
18.

STAT-1-mediated repression of monocyte interleukin-10 gene expression in vivo.

VanDeusen JB, Shah MH, Becknell B, Blaser BW, Ferketich AK, Nuovo GJ, Ahmer BM, Durbin J, Caligiuri MA.

Eur J Immunol. 2006 Mar;36(3):623-30.

19.

A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.

Notari M, Neviani P, Santhanam R, Blaser BW, Chang JS, Galietta A, Willis AE, Roy DC, Caligiuri MA, Marcucci G, Perrotti D.

Blood. 2006 Mar 15;107(6):2507-16. Epub 2005 Nov 17.

20.

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.

Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, Roy DC, Valtieri M, Bruner-Klisovic R, Caligiuri MA, Bloomfield CD, Marcucci G, Perrotti D.

Cancer Cell. 2005 Nov;8(5):355-68.

21.

IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease.

Roychowdhury S, Blaser BW, Freud AG, Katz K, Bhatt D, Ferketich AK, Bergdall V, Kusewitt D, Baiocchi RA, Caligiuri MA.

Blood. 2005 Oct 1;106(7):2433-5. Epub 2005 Jun 23.

22.

Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.

Roychowdhury S, Baiocchi RA, Vourganti S, Bhatt D, Blaser BW, Freud AG, Chou J, Chen CS, Xiao JJ, Parthun M, Chan KK, Eisenbeis CF, Ferketich AK, Grever MR, Chen CS, Caligiuri MA.

J Natl Cancer Inst. 2004 Oct 6;96(19):1447-57.

PMID:
15467034
23.

Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease.

Blaser BW, Roychowdhury S, Kim DJ, Schwind NR, Bhatt D, Yuan W, Kusewitt DF, Ferketich AK, Caligiuri MA, Guimond M.

Blood. 2005 Jan 15;105(2):894-901. Epub 2004 Sep 16.

24.

New directions in natural killer cell-based immunotherapy of human cancer.

Farag SS, Fehniger TA, Becknell B, Blaser BW, Caligiuri MA.

Expert Opin Biol Ther. 2003 Apr;3(2):237-50. Review.

PMID:
12662139

Supplemental Content

Loading ...
Support Center